Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

29.74 +0.18 (+0.61%)

Streaming Delayed Price Updated: 10:44 AM EDT, Aug 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	186,503
Open	28.78
Bid (Size)	29.65 (100)
Ask (Size)	29.83 (200)
Prev. Close	29.56
Today's Range	28.78 - 31.00
52wk Range	12.71 - 40.22
Shares Outstanding	44,188,534
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Stoke Therapeutics Q2 Earnings Call Highlights ↗

August 03, 2026

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion...

Via MarketBeat

Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates

August 03, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Performance

YTD	-3.8%	-3.8%
1 Month	-8.3%	-8.3%
3 Month	-13.0%	-13.0%
6 Month	-3.3%	-3.3%
1 Year	+126.3%	+126.3%

More News

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

July 27, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

July 16, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion ↗

May 07, 2026

Via Chartmill

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

July 13, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

June 30, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

June 16, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

May 28, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 18, 2026

From Stoke Therapeutics

Via Business Wire

Stoke Therapeutics Q1 Earnings Call Highlights ↗

May 09, 2026

Via MarketBeat

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

May 07, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates

April 30, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

April 16, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

April 08, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

April 07, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares ↗

March 27, 2026

Via The Motley Fool

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

Via MarketMinute

Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally ↗

March 24, 2026

Via The Motley Fool

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 17, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 04, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 04, 2026

From Biogen Inc.

Via GlobeNewswire

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Stoke Therapeutics, Inc.

Via Business Wire

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

Via The Motley Fool

Frequently Asked Questions

Is Stoke Therapeutics, Inc. - Common Stock publicly traded?

Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?

Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?

The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market

What is the current price of Stoke Therapeutics, Inc. - Common Stock?

The current price of Stoke Therapeutics, Inc. - Common Stock is 29.74

When was Stoke Therapeutics, Inc. - Common Stock last traded?

The last trade of Stoke Therapeutics, Inc. - Common Stock was at 08/04/26 10:44 AM ET

What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?

The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.31B

How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?

Stoke Therapeutics, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.